Beyond Genomics
Author:
- 1 October 2007
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 82 (4) , 366-370
Abstract
The sequencing of the human genome has already had an enormous impact on medicine, particularly with single-gene changes that predispose to a serious disease such as cystic fibrosis or the overexpression of Her2 in about one-third of breast cancers. Genetic technology has led to some very important therapeutic innovations, including the use of imatinib mesylate (Gleevec) in BCR-ABL chronic myeloid leukemia and of trastuzumab (Herceptin) in Her2-positive breast cancer, but the much anticipated explosion of new effective treatments has been more modest than expected.Keywords
This publication has 8 references indexed in Scilit:
- Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controlsNature, 2007
- Lifting the Fog around AnesthesiaScientific American, 2007
- A Common Variant in the FTO Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult ObesityScience, 2007
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412New England Journal of Medicine, 2006
- Improving Adherence Persistence: A Review Assessment of Interventions Description of Steps Toward a National Adherence InitiativeJournal of the American Pharmacists Association, 2003
- A strategy to reduce cardiovascular disease by more than 80%BMJ, 2003
- The druggable genomeNature Reviews Drug Discovery, 2002
- Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.Journal of Clinical Investigation, 1996